keyword
MENU ▼
Read by QxMD icon Read
search

Predictive biomarkers bevacizumab

keyword
https://www.readbyqxmd.com/read/27868413/-progress-on-clinical-application-of-bevacizumab-for-the-treatment-of-refractory-cervical-cancer
#1
Bin He, Yanlan Chai, Tao Wang, Zhenxing Zhou, Zi Liu
Bevacizumab is increasingly used in recurrent, persistent or metastatic cervical cancer. The early retrospective case reports found that bevacizumab combined with 5-FU (including capecitabine) or paclitaxel was well tolerated and displayed encouraging anti-tumor activity in recurrent or persistent cervical cancer. Phase Ⅱ clinical trials showed that bevacizumab was well tolerated and active in the second- and third-line treatment of patients with recurrent cervical cancer. Large scale phase Ⅱ and phase Ⅲ clinical trials demonstrated that bevacizumab-containing chemotherapy was effective in the first- and second-line treatment of patients with persistent cervical cancer, prolonged survival time and improved remission rate...
May 25, 2016: Zhejiang da Xue Xue Bao. Yi Xue Ban, Journal of Zhejiang University. Medical Sciences
https://www.readbyqxmd.com/read/27843607/association-between-bevacizumab-related-hypertension-and-response-to-treatment-in-patients-with-metastatic-colorectal-cancer
#2
Isabel José Dionísio de Sousa, Joana Ferreira, Joana Rodrigues, Nuno Bonito, Paula Jacinto, Mariela Marques, João Ribeiro, Ana Pais, Helena Gervásio
BACKGROUND: Bevacizumab has become standard of care as first-line treatment of metastatic colorectal cancer (mCRC), after proving increased response rates and improvement in survival outcomes. Hypertension (HTN) is a common complication of the treatment with bevacizumab and, owing to its close relation with antiangiogenic mechanism, may represent a clinical biomarker to predict the efficacy of the treatment. The aim of this study was to retrospectively evaluate if HTN grades 2 to 3 were correlated with response to treatment with bevacizumab in first line, as well as with improved progression-free survival (PFS) and overall survival (OS), in a series of patients with mCRC...
2016: ESMO Open
https://www.readbyqxmd.com/read/27817944/bevacizumab-plus-paclitaxel-versus-placebo-plus-paclitaxel-as-first-line-therapy-for-her2-negative-metastatic-breast-cancer-meridian-a-double-blind-placebo-controlled-randomised-phase-iii-trial-with-prospective-biomarker-evaluation
#3
David Miles, David Cameron, Igor Bondarenko, Lyudmila Manzyuk, Juan Carlos Alcedo, Roberto Ivan Lopez, Seock-Ah Im, Jean-Luc Canon, Yaroslav Shparyk, Denise A Yardley, Norikazu Masuda, Jungsil Ro, Neelima Denduluri, Stanislas Hubeaux, Cheng Quah, Carlos Bais, Joyce O'Shaughnessy
AIM: MERiDiAN evaluated plasma vascular endothelial growth factor-A (pVEGF-A) prospectively as a predictive biomarker for bevacizumab efficacy in metastatic breast cancer (mBC). METHODS: In this double-blind placebo-controlled randomised phase III trial, eligible patients had HER2-negative mBC previously untreated with chemotherapy. pVEGF-A was measured before randomisation to paclitaxel 90 mg/m(2) on days 1, 8 and 15 with either placebo or bevacizumab 10 mg/kg on days 1 and 15, repeated every 4 weeks until disease progression, unacceptable toxicity or consent withdrawal...
November 4, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27803067/large-scale-radiomic-profiling-of-recurrent-glioblastoma-identifies-an-imaging-predictor-for-stratifying-anti-angiogenic-treatment-response
#4
Philipp Kickingereder, Michael Götz, John Muschelli, Antje Wick, Ulf Neuberger, Russell T Shinohara, Martin Sill, Martha Nowosielski, Heinz-Peter Schlemmer, Alexander Radbruch, Wolfgang Wick, Martin Bendszus, Klaus H Maier-Hein, David Bonekamp
PURPOSE: Antiangiogenic treatment with bevacizumab, a mAb to the VEGF, is the single most widely used therapeutic agent for patients with recurrent glioblastoma. A major challenge is that there are currently no validated biomarkers that can predict treatment outcome. Here we analyze the potential of radiomics, an emerging field of research that aims to utilize the full potential of medical imaging. EXPERIMENTAL DESIGN: A total of 4,842 quantitative MRI features were automatically extracted and analyzed from the multiparametric tumor of 172 patients (allocated to a discovery and validation set with a 2:1 ratio) with recurrent glioblastoma prior to bevacizumab treatment...
December 1, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27782226/-the-evolution-of-the-treatment-of-advanced-nsclc
#5
Alessandro Morabito
The therapeutic scenario of patients with advanced non-small-cell lung cancer (NSCLC) has dramatically changed in recent years, thanks to the improvement in the knowledge of the biology of NSCLC, the discovery of targetable oncogenic drivers, and the availability of new effective drugs also for non oncogenic addicted patients, defined "wild-type" (WT). NSCLC has been the first epithelial neoplasm treated with a targeted first-line therapy in patients harbouring EGFR activating mutations or ALK rearrangements, and new targeted-based agents directed versus other molecular alterations are currently in development...
October 2016: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/27712015/a-randomized-study-of-folfiri-plus-either-panitumumab-or-bevacizumab-for-wild-type-kras-colorectal-cancer-wjog-6210g
#6
Kohei Shitara, Kimio Yonesaka, Tadamichi Denda, Kentaro Yamazaki, Toshikazu Moriwaki, Masahiro Tsuda, Toshimi Takano, Hiroyuki Okuda, Tomohiro Nishina, Kazuko Sakai, Kazuto Nishio, Shoji Tokunaga, Takeharu Yamanaka, Narikazu Boku, Ichinosuke Hyodo, Kei Muro
This randomized phase II trial compared panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) with bevacizumab plus FOLFIRI as second-line chemotherapy for wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and to explore the values of oncogenes in circulating tumor DNA (ctDNA) and serum proteins as predictive biomarkers. Patients with WT KRAS exon 2 mCRC refractory to first-line chemotherapy containing oxaliplatin and bevacizumab were randomly assigned to panitumumab plus FOLFIRI or bevacizumab plus FOLFIRI...
October 6, 2016: Cancer Science
https://www.readbyqxmd.com/read/27664394/improvement-in-survival-end-points-of-patients-with-metastatic-renal-cell-carcinoma-through-sequential-targeted-therapy
#7
Emiliano Calvo, Manuela Schmidinger, Daniel Y C Heng, Viktor Grünwald, Bernard Escudier
Survival of patients with metastatic renal cell carcinoma (mRCC) has improved since the advent of targeted therapy. Approved agents include the multi-targeted tyrosine kinase inhibitors (TKIs) sunitinib, sorafenib, axitinib, pazopanib, cabozantinib, and lenvatinib (approved in combination with everolimus), the anti-VEGF monoclonal antibody bevacizumab, the mammalian target of rapamycin (mTOR) inhibitors everolimus and temsirolimus, and the programmed death-1 (PD-1) targeted immune checkpoint inhibitor nivolumab...
September 10, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27626306/assessment-of-bevacizumab-resistance-increased-by-expression-of-bcat1-in-idh1-wild-type-glioblastoma-application-of-dsc-perfusion-mr-imaging
#8
Hye Rim Cho, Bora Hong, Hyeonjin Kim, Chul-Kee Park, Sung-Hye Park, Sunghyouk Park, Seung Hong Choi
BCAT1 (branched-chain amino acid trasaminase1) expression is necessary for the progression of IDH1 wild-type (WT) glioblastoma multiforme (GBM), which is known to be associated with aggressive tumors. The purpose of our study is to investigate the bevacizumab resistance increased by the expression of BCAT1 in IDH1 WT GBM in a rat model, which was evaluated using DSC perfusion MRI. BCAT1 sh#1 inhibits cell proliferation and limits cell migration potential in vitro. In vivo MRI showed that the increase in both tumor volume and nCBV after bevacizumab treatment in IDH1 WT tumors was significantly higher compared with BCAT1 sh#1tumors...
September 8, 2016: Oncotarget
https://www.readbyqxmd.com/read/27621699/everolimus-in-the-management-of-metastatic-renal-cell-carcinoma-an-evidence-based-review-of-its-place-in-therapy
#9
REVIEW
Sebastiano Buti, Alessandro Leonetti, Alice Dallatomasina, Melissa Bersanelli
INTRODUCTION: Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, and its pathogenesis is strictly related to altered cellular response to hypoxia, in which mTOR signaling pathway is implicated. Everolimus, an mTOR serine/threonine kinase inhibitor, represents a therapeutic option for the treatment of advanced RCC. AIM: The objective of this article is to review the evidence for the treatment of metastatic RCC with everolimus. EVIDENCE REVIEW: Everolimus was approved for second- and third-line therapy in patients with advanced RCC according to the results of a Phase III pivotal trial that demonstrated a benefit in median progression-free survival of ~2 months compared to placebo after failure of previous lines of therapy, of which at least one was an anti-VEGFR tyrosine kinase inhibitor (TKI)...
2016: Core Evidence
https://www.readbyqxmd.com/read/27575850/a-functional-bioassay-to-determine-the-activity-of-anti-vegf-antibody-therapy-in-blood-of-patients-with-cancer
#10
Madelon Q Wentink, Henk J Broxterman, Siu W Lam, Epie Boven, Maudy Walraven, Arjan W Griffioen, Roberto Pili, Hans J van der Vliet, Tanja D de Gruijl, Henk M W Verheul
BACKGROUND: Only a small proportion of patients respond to anti-VEGF therapy, pressing the need for a reliable biomarker that can identify patients who will benefit. We studied the biological activity of anti-VEGF antibodies in patients' blood during anti-VEGF therapy by using the Ba/F3-VEGFR2 cell line, which is dependent on VEGF for its growth. METHODS: Serum samples from 22 patients with cancer before and during treatment with bevacizumab were tested for their effect on proliferation of Ba/F3-VEGFR2 cells...
October 11, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27568331/blood-based-biomarkers-for-monitoring-antiangiogenic-therapy-in-non-small-cell-lung-cancer
#11
Analia Rodríguez Garzotto, C Vanesa Díaz-García, Alba Agudo-López, Elena Prieto García, Santiago Ponce, José A López-Martín, Luis Paz-Ares, Lara Iglesias, M Teresa Agulló-Ortuño
Tumor angiogenesis pathways have been identified as important therapeutic targets in non-small cell lung cancer. However, no biomarkers have been described as predictors of response to antiangiogenic therapy in these patients. In this study, plasma levels of VEGF, bFGF, E-selectin, and S-ICAM and gene expression profiles of peripheral blood mononuclear cells from non-small cell lung cancer patients treated with chemotherapy plus bevacizumab were analyzed before and after treatment. Values were correlated with clinicopathological characteristics and treatment response...
October 2016: Medical Oncology
https://www.readbyqxmd.com/read/27557121/geometrical-measures-obtained-from-pretreatment-postcontrast-t1-weighted-mris-predict-survival-benefits-from-bevacizumab-in-glioblastoma-patients
#12
David Molina, Julián Pérez-Beteta, Alicia Martínez-González, Juan M Sepúlveda, Sergi Peralta, Miguel J Gil-Gil, Gaspar Reynes, Ana Herrero, Ramón De Las Peñas, Raquel Luque, Jaume Capellades, Carmen Balaña, Víctor M Pérez-García
BACKGROUND: Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unable to extend survival in large patient cohorts. However, a subset of patients having angiogenesis-dependent tumors might benefit from these therapies. Currently, there are no biomarkers allowing to discriminate responders from non-responders before the start of the therapy. METHODS: 40 patients from the randomized GENOM009 study complied the inclusion criteria (quality of images, clinical data available)...
2016: PloS One
https://www.readbyqxmd.com/read/27551256/update-on-anti-angiogenesis-therapy-in-colorectal-cancer
#13
Kristen K Ciombor, Richard M Goldberg
Angiogenesis is a complex biologic process critical to growth and proliferation of colorectal cancer. The safety and efficacy of various anti-angiogenic agents have been investigated in many treatment settings. Bevacizumab, an anti-vascular endothelial growth factor agent, has efficacy in both the first-line setting and beyond progression in metastatic colorectal cancer. The decoy vascular endothelial growth factor receptor aflibercept has been approved in combination with 5-fluorouracil, leucovorin and irinotecan-based chemotherapy in metastatic colorectal cancer patients whose disease has progressed on a prior oxaliplatin-based chemotherapy regimen...
December 2015: Current Colorectal Cancer Reports
https://www.readbyqxmd.com/read/27535973/expression-of-genes-involved-in-vascular-morphogenesis-and-maturation-predicts-efficacy-of-bevacizumab-based-chemotherapy-in-patients-undergoing-liver-resection
#14
Stefan Stremitzer, Wu Zhang, Dongyun Yang, Yan Ning, Yu Sunakawa, Satoshi Matsusaka, Anish Parekh, Satoshi Okazaki, Diana Hanna, Stephanie H Astrow, Miriana Moran, Jose Hernandez, Craig Stephens, Stefan J Scherer, Judith Stift, Friedrich Wrba, Thomas Gruenberger, Heinz-Josef Lenz
Angiogenesis-related gene expression is associated with the efficacy of anti-VEGF therapy. We tested whether intratumoral mRNA expression levels of genes involved in vascular morphogenesis and early vessel maturation predict response, recurrence-free survival (RFS), and overall survival (OS) in a unique cohort of patients with colorectal liver metastases (CLM) treated with bevacizumab-based chemotherapy followed by curative liver resection. Intratumoral mRNA was isolated from resected bevacizumab-pretreated CLM from 125 patients...
August 17, 2016: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/27502701/selection-of-an-early-biomarker-for-vascular-normalization-using-dynamic-contrast-enhanced-ultrasonography-to-predict-outcomes-of-metastatic-patients-treated-with-bevacizumab
#15
N Lassau, B Coiffier, M Kind, V Vilgrain, J Lacroix, M Cuinet, S Taieb, R Aziza, A Sarran, C Labbe-Devilliers, B Gallix, O Lucidarme, Y Ptak, L Rocher, L M Caquot, S Chagnon, D Marion, A Luciani, S Feutray, J Uzan-Augui, B Benatsou, J Bonastre, S Koscielny
BACKGROUND: Dynamic contrast-enhanced ultrasonography (DCE-US) has been used for evaluation of tumor response to antiangiogenic treatments. The objective of this study was to assess the link between DCE-US data obtained during the first week of treatment and subsequent tumor progression. PATIENTS AND METHODS: Patients treated with antiangiogenic therapies were included in a multicentric prospective study from 2007 to 2010. DCE-US examinations were available at baseline and at day 7...
October 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27498762/a-vegf-dependent-gene-signature-enriched-in-mesenchymal-ovarian-cancer-predicts-patient-prognosis
#16
Xia Yin, Xiaojie Wang, Boqiang Shen, Ying Jing, Qing Li, Mei-Chun Cai, Zhuowei Gu, Qi Yang, Zhenfeng Zhang, Jin Liu, Hongxia Li, Wen Di, Guanglei Zhuang
We have previously reported surrogate biomarkers of VEGF pathway activities with the potential to provide predictive information for anti-VEGF therapies. The aim of this study was to systematically evaluate a new VEGF-dependent gene signature (VDGs) in relation to molecular subtypes of ovarian cancer and patient prognosis. Using microarray profiling and cross-species analysis, we identified 140-gene mouse VDGs and corresponding 139-gene human VDGs, which displayed enrichment of vasculature and basement membrane genes...
2016: Scientific Reports
https://www.readbyqxmd.com/read/27487142/blood-baseline-neutrophil-count-predicts-bevacizumab-efficacy-in-glioblastoma
#17
Aurélie Bertaut, Caroline Truntzer, Rachid Madkouri, Coureche Guillaume Kaderbhai, Valentin Derangère, Julie Vincent, Bruno Chauffert, Marie Hélene Aubriot-Lorton, Wahlid Farah, Klaus Luc Mourier, Romain Boidot, Francois Ghiringhelli
Bevacizumab is used to treat glioblastoma; however, no current biomarker predicts its efficacy. We used an exploratory cohort of patients treated with the radiochemotherapy then bevacizumab or chemotherapy at recurrence (N = 265). Bevacizumab use increased median overall survival (OS) 18.7 vs 11.3 months, p = 0.0014). In multivariate analysis, age, initial surgery, neutrophil count, Karnofsky status >70% and bevacizumab administration were independent prognostic factors of survival. We found an interaction between bevacizumab use and baseline neutrophil count...
July 28, 2016: Oncotarget
https://www.readbyqxmd.com/read/27468218/total-and-not-bevacizumab-bound-vascular-endothelial-growth-factor-as-potential-predictive-factors-to-bevacizumab-based-chemotherapy-in-colorectal-cancer
#18
Amalia Azzariti, Letizia Porcelli, Oronzo Brunetti, Marzia Del Re, Vito Longo, Patrizia Nardulli, Michele Signorile, Jian-Ming Xu, Angela Calabrese, Anna Elisa Quatrale, Evaristo Maiello, Vito Lorusso, Nicola Silvestris
AIM: To identify suitable biomarkers of response to bevacizumab (BV) - it remains an open question. The measurement of serum vascular endothelial growth factor (VEGF) has been proposed as a predictive factor for this drug, even if literature data are contradictory. METHODS: We prospectively evaluated the role of BV, total and not BV-bound VEGF and angiopoietin-2 (Ang-2) serum levels as potential predictive factors of response for BV in combination with an oxaliplatin-based chemotherapy...
July 21, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27463642/the-evolving-role-of-monoclonal-antibodies-in-the-treatment-of-patients-with-advanced-renal-cell-carcinoma-a-systematic-review
#19
Giuseppe Di Lorenzo, Sabino De Placido, Martina Pagliuca, Matteo Ferro, Giuseppe Lucarelli, Sabrina Rossetti, Davide Bosso, Livio Puglia, Piero Pignataro, Ilaria Ascione, Ottavio De Cobelli, Michele Caraglia, Michele Aieta, Daniela Terracciano, Gaetano Facchini, Carlo Buonerba, Guru Sonpavde
INTRODUCTION: While the majority of the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors currently used for the therapy of metastatic renal cell carcinoma (mRCC) are small molecule agents inhibiting multiple targets, monoclonal antibodies are inhibitors of specific targets, which may decrease off-target effects while preserving on-target activity. A few monoclonal antibodies have already been approved for mRCC (bevacizumab, nivolumab), while many others may play an important role in the therapeutic scenario of mRCC...
July 27, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27401244/baton-crc-a-phase-ii-randomized-trial-comparing-tivozanib-plus-mfolfox6-with-bevacizumab-plus-mfolfox6-in-stage-iv-metastatic-colorectal-cancer
#20
Al B Benson, Igor Kiss, John Bridgewater, Ferry A L M Eskens, Carolyn Sasse, Sandra Vossen, Jihong Chen, Chip Van Sant, Howard A Ball, Anne Keating, Andrew Krivoshik
PURPOSE: Tivozanib, a selective inhibitor of VEGFR-1, -2, and -3, plus mFOLFOX6 in an advanced gastrointestinal cancer phase Ib study had encouraging antineoplastic activity and a tolerable safety profile. This randomized, open-label, phase II trial of tivozanib/mFOLFOX6 versus bevacizumab/mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (mCRC) evaluated tivozanib activity versus bevacizumab. EXPERIMENTAL DESIGN: Treatment-naïve patients received mFOLFOX6 every 2 weeks of each 28-day cycle plus either tivozanib orally 1...
July 11, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
80323
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"